Cosmetic composition for aiding skin soothing by adding madecassoside and panthenol

A composition of dipotassium glycyrrhizate, madecassoside, and panthenol addresses skin aging and inflammation by strengthening the skin barrier, regenerating skin, and providing anti-aging benefits, effectively treating inflammatory skin diseases.

WO2026235316A1PCT designated stage Publication Date: 2026-11-12TORRIDEN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/005722
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-17
Filing Date
2026-04-29
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing skin care compositions fail to effectively address skin aging, inflammation, and inflammatory skin diseases, with a need for natural ingredients that enhance skin barrier, regenerate skin, and provide anti-inflammatory and moisturizing benefits.

Method used

A composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol, optionally with glyceryl glucoside and palmitoyl dipeptide-7, formulated to strengthen the skin barrier, regenerate skin, reduce inflammation, and provide anti-aging and moisturizing effects.

Benefits of technology

The composition significantly enhances skin barrier function, regenerates skin, reduces inflammation, inhibits UV-induced DNA damage, and provides effective moisturization, demonstrating significant anti-aging benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026005722_12112026_PF_FP_ABST
    Figure KR2026005722_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel composition for improving skin. The composition for improving skin according to the present invention was confirmed, in human-derived skin tissues, to exhibit very excellent effects of strengthening the skin barrier, regenerating the skin, inhibiting skin inflammation, soothing the skin, inhibiting DNA damage caused by ultraviolet rays, inhibiting melanin, and moisturizing. Thus, the composition has an excellent skin improvement effect, that is, an anti-aging effect, and therefore the composition of the present invention can be variously used in the field of skin improvement and the field of treating inflammatory skin diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Cosmetic composition that helps soothe the skin by adding madecassoside and panthenol

[0001] The present invention relates to a novel composition for improving skin, and more specifically, to the use of said composition for strengthening the skin barrier, skin regeneration, suppressing skin inflammation, soothing the skin, suppressing skin photodamage, skin whitening, and skin moisturizing.

[0002] Over time, the skin undergoes a natural aging process, resulting in various signs of aging such as decreased elasticity, wrinkle formation, uneven skin tone, and dryness. Skin aging is broadly classified into intrinsic aging and extrinsic aging; intrinsic aging is caused by genetic factors and hormonal changes, whereas extrinsic aging is accelerated by environmental factors such as ultraviolet rays, pollutants, smoking, and stress.

[0003] In aging skin, the synthesis of key skin-supporting components such as collagen and elastin decreases, while the activity of degrading enzymes increases, leading to the breakdown of the skin structure. Furthermore, the accumulation of reactive oxygen species (ROS) induces oxidative stress, promoting cell damage and inflammatory responses, which further accelerates the aging process.

[0004] Accordingly, the development of skin-improving compositions containing various functional ingredients, such as antioxidants, collagen synthesis promoters, and anti-inflammatory agents, for the prevention and improvement of skin aging is actively underway. In particular, compositions utilizing naturally derived ingredients or materials with proven biological activity are gaining increasing consumer preference and are attracting attention as an effective means of inhibiting skin aging.

[0005] Accordingly, the inventors prepared a skin-improving composition by mixing components selected from palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol in optimal proportions, and completed the present invention by confirming the significant skin-improving effect thereof.

[0006] Accordingly, the object of the present invention is to provide a composition for skin improvement or anti-aging comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0007] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of inflammatory skin diseases comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0008] Another objective of the present invention is to provide a method for improving skin condition comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0009] Another objective of the present invention is to provide a method for treating inflammatory skin diseases comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0010] To achieve the above objective, the present invention provides a cosmetic composition for improving skin comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0011] In addition, the present invention provides a cosmetic composition for skin anti-aging comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0012] In addition, the present invention provides a quasi-drug composition for improving skin comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0013] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory skin diseases comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0014] In addition, the present invention provides a method for improving skin condition comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0015] In addition, the present invention provides a method for treating inflammatory skin diseases comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0016] It has been confirmed that the skin improvement composition according to the present invention exhibits excellent skin barrier strengthening, skin regeneration, inhibition of skin inflammation, skin soothing, inhibition of DNA damage caused by ultraviolet rays, inhibition of melanin, and moisturizing effects in human-derived skin tissue. This implies that the composition has excellent skin improvement effects, i.e., anti-aging effects, and thus the composition of the present invention can be utilized in various ways in the field of skin improvement and the field of treating inflammatory skin diseases.

[0017] Figure 1 is a figure showing the results of confirming the expression of Loricrin, a skin barrier-related factor of the skin improvement composition according to the present invention, in human-derived skin tissue.

[0018] Figure 2 is a figure showing the results of confirming the expression of Serine Palmitoyltransferase, a skin barrier-related factor of the skin improvement composition according to the present invention, in human-derived skin tissue.

[0019] Figure 3 is a figure showing the results of confirming the expression of PCNA, a skin regeneration-related factor of the skin improvement composition according to the present invention, in human-derived skin tissue.

[0020] Figure 4 is a figure showing the results of confirming the expression of IL-6, a skin inflammation-related factor of the skin improvement composition according to the present invention, in human-derived skin tissue.

[0021] Figure 5 is a figure showing the results of confirming the expression of CPD, a factor related to the inhibition of DNA damage caused by UVB, in human-derived skin tissue of the skin improvement composition according to the present invention.

[0022] Figure 6 is a figure showing the results of confirming the expression of melanin in the epidermis of the skin improvement composition according to the present invention in human-derived skin tissue.

[0023] Figure 7 is a figure showing the results of confirming the expression of Aquaporin-3, a skin moisturizing factor of the skin improvement composition according to the present invention, in human-derived skin tissue.

[0024] The present invention will be described in detail below.

[0025] According to an embodiment of the present invention, the present invention provides a skin-improving composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol. The skin-improving composition may be a cosmetic composition or a quasi-drug composition.

[0026] In addition, the present invention provides a cosmetic composition for skin anti-aging comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0027] In the present invention, dipotassium glycyrrhizate is a potassium glycyrrhizinate derived from licorice, and is an ingredient that alleviates inflammatory reactions and exhibits skin soothing and whitening auxiliary effects.

[0028] In the present invention, madecassoside is a triterpenoid saponin contained in Centella asiatica extract, and is useful for promoting the regeneration of damaged skin and maintaining healthy skin through antioxidant and anti-inflammatory actions.

[0029] In the present invention, panthenol is an alcohol derivative of vitamin B5 that is absorbed into the skin and converted into pantothenic acid, and is an effective ingredient for maintaining moisture, strengthening the skin barrier, and alleviating skin irritation.

[0030] In the present invention, it was confirmed that combining the above-mentioned dipotassium glycyrrhizate, madecassoside, and panthenol significantly improves skin barrier strengthening, skin regeneration, inhibition of skin inflammation, skin soothing, inhibition of DNA damage caused by ultraviolet rays, inhibition of melanin, and moisturizing efficacy, and a composition containing this combination was prepared.

[0031] In a specific embodiment of the present invention, dipotassium glycyrrhizate, madecassoside, and panthenol may be mixed in a weight ratio of 0.1 to 5 : 0.1 to 5 : 0.1 to 5, preferably in a weight ratio of 0.5 to 3 : 0.5 to 3 : 0.5 to 3, and most preferably in a weight ratio of 1 : 1 : 1.

[0032] In a specific embodiment of the present invention, the composition further comprises one or more selected from the group consisting of glyceryl glucoside and palmitoyl dipeptide-7.

[0033] In the present invention, glyceryl glucoside is a sugar alcohol derivative in which glycerol and glucose are combined, and has excellent moisture retention ability and is effective in protecting the skin barrier of sensitive or dry skin and promoting cell vitality.

[0034] In the present invention, palmitoyl dipeptide-7 is a lipid-modified peptide in which a dipeptide is bonded to a palmitic acid chain, has excellent skin penetration power, contributes to the promotion of collagen production and wrinkle improvement, and helps soothe irritated skin.

[0035] In a preferred embodiment of the present invention, the palmitoyl dipeptide-7, dipotassium glycyrrhizate, madecassoside, and panthenol may be mixed in a weight ratio of 50 to 200 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5, preferably in a weight ratio of 100 to 150 : 0.5 to 3 : 0.5 to 3 : 0.5 to 3, and most preferably in a weight ratio of 125 : 1 : 1 : 1.

[0036] In a preferred embodiment of the present invention, the glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol may be mixed in a weight ratio of 1 to 50 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5, preferably in a weight ratio of 5 to 25 : 0.5 to 3 : 0.5 to 3 : 0.5 to 3, and most preferably in a weight ratio of 10 : 1 : 1 : 1.

[0037] In a preferred embodiment of the present invention, palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol may be mixed in a weight ratio of 50 to 200 : 1 to 50 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5, preferably in a weight ratio of 100 to 150 : 5 to 25 : 0.5 to 3 : 0.5 to 3 : 0.5 to 3, most preferably in a weight ratio of 125 : 10 : 1 : 1 : 1.

[0038]

[0039] In a specific embodiment of the present invention, the skin improvement is preferably one or more selected from the group consisting of skin barrier strengthening, skin regeneration, inhibition of skin inflammation, skin soothing, inhibition of skin photodamage, skin whitening, and skin moisturization.

[0040] In an embodiment of the present invention, the inventors prepared a skin improvement composition comprising palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol, and confirmed that the composition exhibited significantly higher efficacy in strengthening the skin barrier, skin regeneration, suppressing skin inflammation, soothing the skin, suppressing DNA damage caused by ultraviolet rays, inhibiting melanin, and moisturizing compared to the control group. This implies that the composition has excellent skin improvement effects, i.e., anti-aging effects, and thus the composition of the present invention can be utilized in various ways in the field of skin improvement.

[0041] When the composition according to the present invention is a cosmetic composition, in addition to the above components, it may include conventional cosmetic base components, such as conventional emulsifiers like stabilizers, solubilizers, pigments and fragrances, and carriers. Furthermore, it may be manufactured in any formulation conventionally produced in the cosmetic industry, and although not specifically limited, it may have a formulation such as a lotion, essence, lotion, paste, surfactant-containing cleansing, cream, pack, gel, ointment, powder, patch, or spray.

[0042] In the case where the formulation of the above cosmetic composition is a paste, cream, or gel, one or more selected from the group consisting of animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, and zinc oxide may be used as carrier components, and in the case where the formulation is a lotion or essence, a solvent, a solubilizing agent, or an emulsifying agent may be used as carrier components, for example, one or more selected from the group consisting of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil, glycerol aliphatic ester, polyethylene glycol, and fatty acid ester of sorbitan may be used.

[0043] In addition, if the formulation of the above cosmetic composition is a powder or a spray, one or more selected from the group consisting of lactose, talc, silica, aluminum hydroxide, calcium silicate, and polyamide powder may be used as carrier components, and in particular, if it is a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether. In addition, if the formulation of the above cosmetic composition is a surfactant-containing cleansing agent, one or more selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, and ethoxylated glycerol fatty acid ester may be used as carrier components.

[0044] When the composition of the present invention is a quasi-drug composition, the above-mentioned ingredients may be used as is or together with other quasi-drug ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredients may be appropriately determined according to the purpose of use.

[0045] In the present invention, quasi-drugs refer to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases of humans or animals, among which the effect is milder than that of pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are defined as articles excluding those used for pharmaceutical purposes. These include textile products and rubber products used for the treatment or prevention of diseases in humans and animals, items that have a mild or no direct effect on the human body and are not instruments or machines, and similar items, as well as disinfectants and insecticides for preventing infectious diseases.

[0046] The quasi-drugs for skin improvement according to the present invention are a functional product group that helps strengthen the skin barrier, regenerate the skin, suppress skin inflammation, soothe the skin, suppress skin photodamage, whiten the skin, and moisturize the skin. Examples of quasi-drugs for skin improvement include acne-specific lotions or cleansers that help maintain cleanliness and alleviate inflammation in acne-prone skin, creams containing arbutin or niacinamide for improving blemishes and freckles, sunscreens with UV protection functions, moisturizing creams for alleviating dry skin, Centella gels for wound protection and healing assistance, therapeutic ointments that help heal minor wounds, functional shampoos for alleviating hair loss symptoms, and shampoos used for alleviating dandruff or scalp inflammation.

[0047]

[0048] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory skin diseases comprising dipotassium glycyrrhizate, madecassoside, and panthenol.

[0049] In a specific embodiment of the present invention, the composition further comprises glyceryl glucoside or palmitoyl dipeptide-7.

[0050] In a specific embodiment of the present invention, the inflammatory skin disease may be one or more diseases selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, cutaneous lupus erythematosus, acne vulgaris, eczema, and scleroderma, but the present invention is not limited thereto.

[0051] In an embodiment of the present invention, the inventors prepared a composition comprising palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol, and confirmed that the composition exhibits significantly high efficacy in strengthening the skin barrier, skin regeneration, suppressing skin inflammation, soothing the skin, suppressing DNA damage caused by ultraviolet rays, inhibiting melanin, and moisturizing. In particular, it was confirmed that the composition of the present invention has excellent inhibitory activity against IL-6, a factor related to skin inflammation and skin soothing. Therefore, the composition of the present invention can be utilized in various ways in the field of treating inflammatory skin diseases.

[0052] The composition of the present invention may include one or more known active ingredients having a preventive or therapeutic effect on inflammatory skin diseases.

[0053] The composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, etc.

[0054] The composition of the present invention may be administered in various oral or parenteral formulations during actual clinical administration, and when formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Specific examples of formulations may be referenced in Remington's Pharmaceutical Science et al.

[0055] The above-mentioned solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and starch, calcium carbonate, sucrose, lactose, gelatin, etc. may be used as excipients, and lubricants such as magnesium stearate and talc may also be used.

[0056] Liquid formulations for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may contain humectants, sweeteners, flavorings, preservatives, etc. in addition to water and liquid paraffin.

[0057] Parenteral formulations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories, etc., and propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), injectable esters (e.g., ethyl oleate), etc. may be used as bases for suppositories. Witepsol, Macrogol, Tween 61, cacao oil, laurin oil, glycerozelatin, etc.

[0058] The above parenteral administration may be performed via external application to the skin or by intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or thoracic injection.

[0059] The dosage of the composition of the present invention may vary depending on the patient's body weight, age, gender, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease, and the daily dosage is 0.0001 to 100 mg / kg based on the active ingredient included in the composition of the present invention, preferably 0.001 to 10 mg / kg, and can be administered once a day or divided into several doses.

[0060] The composition of the present invention may be used alone or in combination with steroids, anti-inflammatory agents, antihistamines, immunomodulators, etc., for the prevention and treatment of inflammatory skin diseases.

[0061]

[0062] According to another aspect of the present invention, the present invention provides a method for improving skin condition comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0063] In a specific embodiment of the present invention, the improvement of the skin condition may be skin moisturization, skin regeneration, improvement of skin wrinkles, enhancement of skin elasticity, alleviation of skin irritation, skin soothing, or anti-aging.

[0064] In a specific embodiment of the present invention, the individual may be an individual expected to require skin improvement, specifically an individual requiring effects such as skin moisturization, whitening, wrinkle improvement, skin regeneration, antioxidant or skin barrier improvement, but is not limited thereto.

[0065] In a specific embodiment of the present invention, the composition may be in the form of a cosmetic composition, a quasi-drug composition, or a pharmaceutical composition, but is not limited thereto. The cosmetic composition may be provided in various formulations such as skin, toner, essence, serum, ampoule, lotion, cream, gel, oil, mist, patch, or mask pack, and may additionally include emulsifiers, moisturizers, thickeners, stabilizers, antioxidants, fragrances, colorants, and preservatives used in conventional cosmetic compositions. The quasi-drug composition may be provided in external formulations such as ointments, creams, gels, lotions, sprays, or patches for skin protection or improvement. The pharmaceutical composition may include a pharmaceutically acceptable carrier, and the carrier may include physiological saline, a buffer solution, a solvent, a dispersant, or a stabilizer. The pharmaceutical composition may be applied in a parenteral form including external application to the skin, but is not limited thereto.

[0066]

[0067] According to another aspect of the present invention, the present invention provides a method for treating an inflammatory skin disease comprising the step of administering a composition comprising dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.

[0068] In a specific embodiment of the present invention, the individual may be an individual expected to develop an inflammatory skin disease; an individual that has developed the disease; or an individual that has been determined to be cured, but is not limited thereto.

[0069]

[0070] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs.

[0071] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0072]

[0073] Preparation Example 1. Preparation of a skin-improving composition

[0074] A skin-improving composition was prepared by mixing palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol. Specifically, the raw materials were each added to and mixed with purified water containing 2% 1,2-hexanediol according to the weight ratios shown in Table 1 below.

[0075] Sample Name Control Group 1 Example 1 Example 2 Example 3 Palmitoyl Dipeptide-7 0.0000% 0.1250% 0.0000% 0.1250% Glyceryl glucoside 0.0000% 0.0000% 0.0100% 0.0100% Dipotassium Glycyrrhizate 0.0000% 0.0010% 0.0010% 0.0010% Madecassoside 0.0000% 0.0010% 0.0010% 0.0010% Panthenol 0.0000% 0.0010% 0.0010% 0.0010% Sodium Sodium Acetate 0.0000% 0.3750% 0.3750% 0.3750% 1,2-Hexanediol 2.0000% 2.0000% 2.0000% 2.0000% Water 98.0000% 97.4970% 97.6120% 97.4870% Total 100.0000% 100.0000% 100.0000% 100.0000%

[0076] Each mixture was introduced into a water-jacketed reactor capable of maintaining temperature, and then heated (55-65°C) and stirred (700 rpm, for at least 4 hours). The mixture, after stirring was complete, was first filtered through a 100 μm Cellulose Acetate filter and then secondarily filtered through a 0.22 μm PVDF filter. The product obtained from the second filtration was used in the following experiments after confirming through microbiological testing that harmful microorganisms capable of causing skin irritation had been removed. The prepared skin-improving composition was named 'T-Focusing Control Complex'.

[0077]

[0078] Experimental Example 1. Confirmation of skin barrier strengthening efficacy following treatment with a skin-improving composition

[0079] The skin barrier strengthening efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) was confirmed. The skin barrier strengthening efficacy was evaluated by analyzing the expression levels of Loricrin and Serine Palmitoyltransferase, skin barrier-related factors identified in the epidermis, using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2 After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of the skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed in 10% formalin at room temperature for 48 hours. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to prepare a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. Immunohistochemical staining was performed using a lorricrin antibody (Abcam, ab176322) and a serine palmitoyltransferase antibody (Abcam, ab236900) to determine the expression levels of lorricrin and serine palmitoyltransferase in the epidermis. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the skin barrier strengthening efficacy of the skin improvement composition prepared in Preparation Example 1 are shown in Tables 2 to 3 and Figures 1 to 2.

[0080] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 Loricrin expression (%) 100±49.4 23.9±12.5 477.5±122.7 209.4±96.8 1347.4±390.1

[0081] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 Serine Palmitoyltransferase expression (%) 100±13.8 1.42±0.3 127.8±8.7 101.4±6.8 225.3±10.1

[0082] As shown in Table 2 and Figure 1, it was confirmed that the expression of Loricrin in Examples 1 to 3 was higher than that of control 1 by 453.6%p (Example 1), 185.5%p (Example 2), and 1323.5%p (Example 3), respectively.

[0083] As shown in Table 3 and Figure 2, Examples 1 to 3 were found to have higher expression of Serine Palmitoyltransferase compared to control 1 by 126.4%p (Example 1), 99.9%p (Example 2), and 223.9%p (Example 3), respectively.

[0084] In particular, Example 3 showed significantly higher expression of Loricrin and Serine Palmitoyltransferase compared to Control 1 and other examples. This means that the skin-improving composition of Example 3 has excellent skin barrier strengthening effects.

[0085]

[0086] Experimental Example 2. Confirmation of skin regeneration efficacy following treatment with a skin-improving composition

[0087] The skin regenerative efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) was confirmed. Skin regenerative efficacy was evaluated by analyzing the expression level of PCNA, a skin regeneration-related factor identified in the epidermis, using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, was used. ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed at room temperature for 48 hours with 10% formalin. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to produce a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. Immunohistochemical staining was performed using a PCNA antibody (Abcam, ab92552) to confirm the expression level of PCNA in the epidermis. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the skin regeneration efficacy of the skin improvement composition prepared in Preparation Example 1 are shown in Table 4 and Figure 3.

[0088] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 PCNA expression (%) 100±28.4 21.2±1.8 133.6±49.6 100.3±3 3.4 169.8±70.9

[0089] As shown in Table 4 and Figure 3, it was confirmed that the expression of PCNA in Examples 1 to 3 was 112.4%p (Example 1), 79.1%p (Example 2), and 148.6%p (Example 3), respectively, higher than that of Control 1. In particular, the expression of PCNA in Example 3 was significantly higher than that of Control 1 and other examples. This means that the skin improvement composition of Example 3 has excellent skin regeneration effects.

[0090]

[0091] Experimental Example 3. Confirmation of skin inflammation inhibition and skin soothing efficacy following treatment with a skin-improving composition

[0092] The skin-soothing efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) was confirmed. To evaluate the skin inflammation inhibition and skin-soothing efficacy, the expression level of IL-6, a skin inflammation-related factor identified in the epidermis, was analyzed using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, was used. ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2 After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed at room temperature for 48 hours with 10% formalin. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to produce a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. Immunohistochemical staining was performed using an IL-6 antibody (Abcam, ab6672) to confirm the expression level of IL-6 in the epidermis. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the skin inflammation inhibitory and skin soothing efficacy of the skin improvement composition prepared in Preparation Example 1 are shown in Table 5 and Figure 4.

[0093] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 IL-6 expression (%) 100±3 2.6 101 3.8±2 11.3 203.8±4 4.7 53 4.1±108.7 160.6±8 4.2

[0094] As shown in Table 5 and Figure 4, it was confirmed that the expression of IL-6 in Examples 1 to 3 was lower than that of Control 1 by 810.0%p (Example 1), 479.7%p (Example 2), and 853.2%p (Example 3), respectively. In particular, the expression of IL-6 in Example 3 was significantly lower than that of Control 1 and other examples. This means that the skin improvement composition of Example 3 has excellent effects in inhibiting skin inflammation and soothing the skin.

[0095]

[0096] Experimental Example 4. Confirmation of efficacy in inhibiting UVB-induced DNA damage by treatment with a skin-improving composition

[0097] The efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) in inhibiting UVB-induced DNA damage was confirmed. To evaluate the efficacy of inhibiting UVB-induced DNA damage on the skin, the expression level of CPD, a factor related to the inhibition of UVB-induced DNA damage identified in the epidermis, was analyzed using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed at room temperature for 48 hours with 10% formalin. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to produce a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. Immunohistochemical staining was performed using an IL-6 antibody (Abcam, ab6672) to confirm the expression level of IL-6 in the epidermis. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the efficacy of the skin improvement composition prepared in Preparation Example 1 in inhibiting DNA damage caused by UVB on the skin are shown in Table 6 and Figure 5.

[0098] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 CPD expression (%) 100±6 0.3 27 82.3±6 5 5.5 23 3.7±5 2.6 6 27.7±2 11.3 18 4.7±8 1.8

[0099] As shown in Table 6 and Figure 5, it was confirmed that the expression of CPD in Examples 1 to 3 was lower than that of Control 1 by 2548.6%p (Example 1), 2154.6%p (Example 2), and 2597.6%p (Example 3), respectively. In particular, the expression of CPD in Example 3 was significantly lower than that of Control 1 and other examples. This means that the skin improvement composition of Example 3 has a very excellent effect in inhibiting DNA damage caused by skin UVB.

[0100]

[0101] Experimental Example 5. Confirmation of melanin-inhibiting efficacy by treatment with a skin-improving composition

[0102] The melanin-inhibiting efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) was confirmed. Melanin-inhibiting efficacy was evaluated by analyzing the level of melanin detected in the epidermis using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2 After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed at room temperature for 48 hours with 10% formalin. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to produce a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. To determine the level of melanin in the epidermis of the skin, the tissue sections were stained using the Fontana-Mason staining method, a special staining technique that specifically stains melanin. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the efficacy of the skin improvement composition prepared in Preparation Example 1 in inhibiting DNA damage caused by UVB on the skin are shown in Table 7 and Figure 6.

[0103] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 Melanin expression (%) 100±5 8.23 ​​11.2±24.7 20 4.6±27.7 30 1.1±7 3.5 17 4.0±36.8

[0104] As shown in Table 7 and Figure 6, it was confirmed that the melanin expression in Examples 1 to 3 was lower than that of Control 1 by 126.3%p (Example 1), 118.0%p (Example 2), and 185.1%p (Example 3), respectively. In particular, the melanin expression in Example 3 was significantly lower than that of Control 1 and other examples. This means that the skin improvement composition of Example 3 has excellent skin whitening effects.

[0105]

[0106] Experimental Example 6. Confirmation of skin moisturizing efficacy following treatment with a skin-improving composition

[0107] The skin moisturizing efficacy of the skin-improving composition prepared in Preparation Example 1 (Control Group 1, Examples 1-3) was confirmed. Skin moisturizing efficacy was assessed by analyzing the expression level of Aquaporin-3, a skin moisturization-related factor identified in the epidermis, using human-derived skin tissue. Specifically, NativSkin access, manufactured for research purposes by Genoskin of France, was used. ® [The following text appears to be gibberish and likely an incomplete sentence] was used for the evaluation. The received skin tissues were stabilized for 1 hour before use, and UVB 50 mJ / cm² was applied to tissues excluding the normal tissue group. 2After investigation, approximately 25 µl of the sample from Preparation Example 1 was applied to the surface of skin tissue and cultured for 48 hours. After 48 hours, the skin tissue was collected, washed, and fixed at room temperature for 48 hours with 10% formalin. After fixation, the tissue was washed with running water, dehydrated, and embedded in paraffin to produce a paraffin block. The prepared paraffin block was sectioned into 5 µl portions to prepare tissue sections. Immunohistochemical staining was performed using an Aquaporin-3 antibody (Abcam, ab125129) to confirm the expression level of Aquaporin-3 in the epidermis. The stained tissue sections were analyzed under a microscope. The acquired images were analyzed using the Image J (NIH, USA) program. The results confirming the skin regeneration efficacy of the skin improvement composition prepared in Preparation Example 1 are shown in Table 8 and Figure 7.

[0108] Normal tissue group Control group Example 1 Example 1 Example 2 Example 3 Aquaporin-3 expression (%) 100±27.0 7.1±3.8 133.4±18.8 125.1±16.7 192.2±29.4

[0109] As shown in Table 8 and Figure 7, it was confirmed that the expression of Aquaporin-3 in Examples 1 to 3 was higher than that of Control 1 by 126.3%p (Example 1), 118.0%p (Example 2), and 185.1%p (Example 3), respectively. In particular, the expression of Aquaporin-3 in Example 3 was significantly higher than that of Control 1 and other examples. This means that the skin improvement composition of Example 3 has excellent skin moisturizing effects.

[0110]

[0111] Experimental Example 7. Confirmation of skin irritation level following treatment with a skin-improving composition

[0112] The skin reactivity of the skin improvement composition prepared in Preparation Example 1 (Example 3) was confirmed. Specifically, a patch containing the prepared skin improvement composition was applied to the back (excluding the spinal area) for 24 hours. Skin irritation was first assessed 30 minutes after patch removal and secondly assessed 24 hours after patch removal. The final skin irritation level was determined based on the results of the first and second assessments. The results of the skin irritation level assessment are shown in Table 9.

[0113] Sample Name Number of Respondents Skin Reactivity Average Skin Reactivity Assessment 30 min 24 hr Example 3 None 00 None Non-irritating Distilled Water (Negative Control) None 00 None Non-irritating Blank None 00 None Non-irritating

[0114] As shown in Table 9, the skin improvement composition prepared in Preparation Example 1 (Example 3) showed a skin reactivity of 0 up to 24 hours, and was judged to be 'non-irritating' with no irritation to the skin.

[0115]

[0116] In summary, the inventors have prepared a skin improvement composition comprising palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol, and confirmed that the composition exhibits significantly higher efficacy in strengthening the skin barrier, regenerating the skin, suppressing skin inflammation, soothing the skin, inhibiting DNA damage caused by ultraviolet rays, suppressing melanin, and moisturizing compared to the control group. This implies that the composition has excellent skin improvement effects, i.e., anti-aging effects, and thus the composition of the present invention can be utilized in various ways in the field of skin improvement and the field of treating inflammatory skin diseases.

[0117]

[0118] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

A cosmetic composition for improving skin comprising dipotassium glycyrrhizate, madecassoside, and panthenol. A cosmetic composition for improving skin according to claim 1, wherein dipotassium glycyrrhizate, madecassoside, and panthenol are mixed in a weight ratio of 0.1 to 5 : 0.1 to 5 : 0.1 to 5. A cosmetic composition for skin improvement according to claim 1, wherein the composition further comprises one or more selected from the group consisting of glyceryl glucoside and palmitoyl dipeptide-7. A cosmetic composition for improving skin according to claim 3, wherein the palmitoyl dipeptide-7, dipotassium glycyrrhizate, madecassoside, and panthenol are mixed in a weight ratio of 50 to 200 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5. A cosmetic composition for improving skin according to claim 3, wherein the glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol are mixed in a weight ratio of 1 to 50 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5. A cosmetic composition for improving skin according to claim 3, wherein palmitoyl dipeptide-7, glyceryl glucoside, dipotassium glycyrrhizate, madecassoside, and panthenol are mixed in a weight ratio of 50 to 200 : 1 to 50 : 0.1 to 5 : 0.1 to 5 : 0.1 to 5. A cosmetic composition for skin improvement according to claim 1, wherein the skin improvement is one or more selected from the group consisting of skin barrier strengthening, skin regeneration, inhibition of skin inflammation, skin soothing, inhibition of skin photodamage, skin whitening, and skin moisturization. A cosmetic composition for skin anti-aging comprising dipotassium glycyrrhizate, madecassoside, and panthenol. A quasi-drug composition for skin improvement comprising dipotassium glycyrrhizate, madecassoside, and panthenol. A pharmaceutical composition for the prevention or treatment of inflammatory skin diseases comprising dipotassium glycyrrhizate, madecassoside, and panthenol. A pharmaceutical composition for the prevention or treatment of inflammatory skin diseases according to claim 10, wherein the inflammatory skin disease is one or more diseases selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, cutaneous lupus erythematosus, acne vulgaris, eczema, and scleroderma. A method for improving skin condition comprising the step of administering a composition containing dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof. A method for treating inflammatory skin diseases comprising the step of administering a composition containing dipotassium glycyrrhizate, madecassoside, and panthenol to an individual in need thereof.